A single infusion of a CRISPR-based therapy has significantly reduced attacks in patients with hereditary angioedema (HAE) in what appears to be the first successful Phase III trial of an in vivo gene-editing treatment. The findings, presented at a major European congress and published in the New England Journal of Medicine, mark a turning point […]
For years, advanced prostate cancer has been the textbook example of an “immunologically cold” tumor: it doesn’t provoke a strong immune response, carries few mutations that help the immune system recognize cancer, and is packed with cells that actively suppress immunity. Because of this, immune checkpoint inhibitors have largely failed in this disease. Against this […]
Cancer therapy has a persistent blind spot. Tumors shrink, biomarkers improve, scans look clean—and yet relapse remains common. The reason is often a tiny population of surviving cells known as persisters. These cells are not genetically resistant. They are identical to the bulk tumor but enter a transient, drug-tolerant state that allows them to survive […]
The phase III PrTK03 trial, reported in The Lancet Oncology, demonstrates that adding aglatimagene besadenovec (CAN-2409) plus valacyclovir to standard radiotherapy improves disease-free survival in patients with localized prostate cancer. Aglatimagene is an intratumoral adenoviral gene therapy that delivers the HSV-tk gene, enabling tumor cells to convert the prodrug valacyclovir into a cytotoxic metabolite that […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Next week I’ll be traveling a bit, but I’ll do my best to keep posting and prepare the next newsletter. For now, here are this week’s news. Stay strong and fight on! As usual, we also have a podcast […]
61Cu-NU101 is a new PSMA-targeted PET/SPECT tracer for prostate cancer that showed promise in phase 1, detecting more lesions than 18F-piflufolastat (Pylarify) in half of the 8 patients studied, with lower background uptake and no side effects. The key advantage is its 3.3-hour half-life, compared to 68 minutes for 68Ga-PSMA-11 and 109 minutes for 18F-piflufolastat. […]
Prostate cancer can become harder to treat when it changes from the usual adenocarcinoma form into neuroendocrine prostate cancer, or NEPC. A recent study suggests that this transition may begin earlier than expected, during an intermediate phase when the cells are still partly prostate-like but are already starting to acquire neuroendocrine features. A central finding […]
Recent real-world data clarify how homologous recombination repair (HRR) alterations, especially BRCA1/2 mutations, affect outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with androgen receptor pathway inhibitors (ARPIs). In a US cohort of 745 patients, overall differences in time-to-next-treatment (TTNT) and time-to-castration resistance (TTCR) were modest between patients without HRR alterations and those with non-BRCA […]
Acoustic cavitation is emerging as a surprisingly powerful tool in the therapeutic landscape of neuroendocrine prostate cancer (NEPC), a disease state notoriously resistant to conventional treatments. By combining nanometer-scale lipid microbubbles with targeted ultrasound, researchers are leveraging a physical mechanism to overcome some of the most entrenched biological barriers in aggressive prostate cancer. At its […]
Rucaparib continues to strengthen its position in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that progresses despite hormonal therapy, with TRITON3 trial confirming not only its efficacy but also a predictable and manageable safety profile. In this phase 3 study of chemotherapy-naïve patients progressing after one prior androgen receptor pathway […]